• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elys Game Technology Joins the U.S. National Council on Problem Gambling in Advance of Launching its Sports Betting Platform in the U.S.

    1/5/21 8:00:00 AM ET
    $ELYS
    $NEO
    Computer Software: Prepackaged Software
    Technology
    Precision Instruments
    Health Care
    Get the next $ELYS alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Elys Game Technology, Corp. (“Elys” or the “Company”) (Nasdaq:ELYS, NEO:ELYS), an interactive gaming and sports betting technology company, announced today that it has joined the National Council on Problem Gambling (NCPG) to further the development and implementation of responsible gambling practices.

    NCPG is a leading U.S. non-governmental organization (NGO) serving as the national advocate for programs and services to assist people and families affected by problem gambling. Through its NCPG membership, Elys will support NCPG‘s wide-ranging problem gambling prevention, treatment, education, and research programs, as well as innovative responsible gambling policies.

    Michele (Mike) Ciavarella, Executive Chairman of Elys Game Technology, Corp., stated, “As we prepare our first U.S. deployment in Washington D.C., we are delighted to become a member of NCPG and support their invaluable work in addressing the critical and widespread need for responsible gambling practices. We are proud to join forces with the esteemed board of directors, members and stakeholders of NCPG to develop and promote national U.S. industry standards in responsible gaming, including the Safer Sports Betting Initiative and Internet Responsible Gambling Standards, which provide critical player services and protections. There is no bigger responsibility for us than ensuring the best and safest possible experience for our gambling operators and their players, while providing assistance for those individuals who show signs of problem gambling behavior. Partnering with NCPG further deepens our commitment to become a leader in responsible gaming and provides us valuable resources as we are preparing for the launch of our sports betting platform in the U.S.”

    Keith Whyte, Executive Director of NCPG, said, “We are excited that Elys has become a member of NCPG, as they bring extensive experience around engaging with millions of players across their sports betting and iGaming platforms. Elys’ broad reach and commitment to responsible gambling will be a tremendous asset to NCPG as we continue raising awareness about problem gambling and the resources available to support those impacted. We look forward to working together with Elys to increase our mutual understanding of player behavior and reduce the risks for gambling problems.”

    Since there is no federal regulation of gambling or federal health insurance for all residents in the U.S., each state makes its own rules to meet its unique structure and goals. B2B and B2C companies like Elys become valuable partners for NCPG, a leading source of objective state-specific information on responsible gambling and problem gambling for the public as well as the gambling industry in the U.S. Companies may create, adapt and update their responsible gambling tools and practices with expert assistance as they work with the varied U.S. state gambling control entities, gambling operators and healthcare providers. In addition, NCPG’s National Problem Gambling Helpline Network is the only source of problem gambling help in many areas of the country. Members like Elys make this possible.

    About Elys Game Technology, Corp.

    Elys Game Technology, Corp., is a B2B global gaming technology company operating in multiple countries worldwide, with B2C online and land-based gaming operations in Italy. In Italy, Elys offers its clients a full suite of leisure gaming products and services, such as sports betting, e-sports, virtual sports, online casino, poker, bingo, interactive games and slots.

    The Company’s innovative wagering solution services online operators, casinos, retail betting establishments and franchise distribution networks. The Company has completed the product regulatory requirements to commence B2B operations in the United States. Additional information is available on our corporate website at www.elysgame.com.

    Investors may also find us on Twitter @ELYS_gaming.

    About the National Council on Problem Gambling

    NCPG is the only U.S. national advocate for people and families affected by problem gambling and is supported by members and donors; there is no federal funding for problem gambling services. NCPG is neutral on legalized gambling and works with all stakeholders to promote responsible gambling. If you or someone you know has a gambling problem, from anywhere in the U.S. you can call or text the National Problem Gambling Helpline Network at 1-800-522-4700 or visit www.ncpgambling.org/chat for confidential help 24/7/365. The call is free and confidential, and translation services are available in over 150 languages.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the Company’s first U.S. deployment in Washington D.C.. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to deploy as planned in Washington, D.C., the duration and scope of the COVID-19 outbreak worldwide, including the impact to the state and local economies, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and its subsequent filings with the U.S. Securities and Exchange Commission, including subsequent periodic reports on Form 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

    Get the next $ELYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELYS
    $NEO

    CompanyDatePrice TargetRatingAnalyst
    NeoGenomics Inc.
    $NEO
    4/29/2026$25.00Market Perform → Outperform
    Leerink Partners
    NeoGenomics Inc.
    $NEO
    7/30/2025Buy → Neutral
    BTIG Research
    NeoGenomics Inc.
    $NEO
    7/29/2025Outperform → Mkt Perform
    William Blair
    NeoGenomics Inc.
    $NEO
    5/15/2025Neutral
    Guggenheim
    NeoGenomics Inc.
    $NEO
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    NeoGenomics Inc.
    $NEO
    1/13/2025Buy → Hold
    The Benchmark Company
    NeoGenomics Inc.
    $NEO
    12/10/2024$22.00Buy
    Jefferies
    NeoGenomics Inc.
    $NEO
    5/1/2024$26.00Buy
    Craig Hallum
    More analyst ratings

    $ELYS
    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Starrett Carolyn S

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    6/25/26 4:09:33 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 3 filed by new insider Starrett Carolyn S

    3 - NEOGENOMICS INC (0001077183) (Issuer)

    6/25/26 4:08:55 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Tetrault Lynn A. sold $58,908 worth of shares (5,307 units at $11.10), decreasing direct ownership by 6% to 86,115 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    6/17/26 4:07:59 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    7/20/26 5:27:16 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    6/25/26 7:10:14 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    6/22/26 5:17:36 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

    NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice ("DOJ") on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services ("OIG") resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021. As the DOJ acknowledged in the settlement agreement, the Company cooperated with the governm

    7/20/26 5:23:00 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

    Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca’s recently approved targeted therapy TRUQAP® (capivasertib).1 PTEN IHC CDx extends the company's reach into

    7/9/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (9

    7/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded NeoGenomics from Market Perform to Outperform and set a new price target of $25.00

    4/29/26 8:00:47 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Carolyn Starrett to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years, from 2016 to 2026, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory

    6/25/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (9

    7/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports First Quarter 2026 Results

    First quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026. First Quarter 2026 Financial Highlights As Compared To First Quarter 2025   Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%   Net loss decreased 34% to $17 million

    4/28/26 4:05:00 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls after market close to allow time for follow-up discussions before the next trading day. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast

    4/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $ELYS
    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care